--- title: "Daiichi Sankyo Company (4568): news, pipeline and catalysts" url: "https://aibio.space/companies/daiichi-sankyo/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Daiichi Sankyo Company news for investors: Daiichi Sankyo is a Japanese drugmaker focused on cancer, best known for the antibody-drug conjugates Enhertu and…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Daiichi Sankyo's ADC engine grows fast but leans on Enhertu Daiichi Sankyo's ADC platform is producing fast revenue growth and a steady flow of breast cancer approvals. Lung cancer is the next test, and 2026 brought a positive Enhertu trial alongside the I-DXd withdrawal. Manufacturing commitments made at peak expectations are a cost of any further pipeline setbacks. Read the full desk view aibio.space Investor Rank · Opinion **8** /10 Positive view The Enhertu-led ADC platform is growing revenue fast with breast cancer approvals, while the I-DXd withdrawal and heavy Enhertu concentration temper the lung cancer case. - **Technology**: 2/2 - **Odds**: 1/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 2/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Proven ADC platform.** Enhertu grew 48.9% in Q1 FY2026 and won two US early breast cancer approvals in May 2026. - **Odds**: **Strong in breast, mixed in lung.** DESTINY-Lung04 met its PFS goal, but the I-DXd small cell lung cancer filing was withdrawn in September 2026. - **Balance sheet**: **Solid.** Cash was JPY 637.9 billion at June 30, 2026, against JPY 500.0 billion of non-current bonds and borrowings. - **Main risk**: **Concentration and supply commitments.** Enhertu is about 42% of revenue, and CMO purchase minimums cost JPY 75.7 billion in fiscal 2025. - **Watch next**: **ESMO and AVANZAR.** ESMO runs October 23 to 27, 2026, and the AVANZAR readout is due in the second half of calendar 2026. ## Top news on Daiichi ## Dates **October 23-27, 2026** ESMO 2026: late-breaking analyses from DESTINY-Lung04 (patient-reported outcomes), DESTINY-Breast09 and TROPION-Breast02 (brain metastases subgroups) [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202610/20261022_E2.pdf) **CY2026 H2** Phase 3 AVANZAR readout for Datroway in first-line NSCLC [Source](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2026/FY2026Q1_Financial_Results_Presentation_E.pdf) **FY2026 H2** Phase 3 TROPION-Lung15 readout for Datroway in EGFR-mutated NSCLC [Source](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2026/FY2026Q1_Financial_Results_Presentation_E.pdf) **April 1, 2027** Ken Keller starts as Chief Commercialization Officer of a new global commercialization unit [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202608/20260824_E.pdf) **June 1, 2027** Scheduled transfer of a further 40% of Daiichi Sankyo Healthcare shares to Suntory [Source](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2026/FY2026Q1_Financial_Results_E.pdf) ## The money Cash and cash equivalents of JPY 637.9 billion at June 30, 2026 (JPY 449.8 billion at March 31, 2026); non-current bonds and borrowings JPY 500.0 billion. Profitable; no runway guidance applies. [Source](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2026/FY2026Q1_Financial_Results_E.pdf) Q1 FY2026 (April to June 2026) revenue JPY 574.7 billion, up 21.1%; Enhertu JPY 239.8 billion and Datroway JPY 23.9 billion including milestones. FY2026 revenue forecast raised to JPY 2.34 trillion. [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202607/20260731_E4.pdf) ## Risks on the record - Daiichi booked a JPY 75.7 billion provision for CMO compensation after lower ADC demand forecasts and has not provisioned the medium- to long-term gap versus minimum purchase obligations. [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202605/20260508_E.pdf) - The US accelerated approval filing for I-DXd in small cell lung cancer was withdrawn after the FDA said phase 2 data were insufficient. [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202609/20260925_E.pdf) - Revenue concentration: Enhertu was JPY 239.8 billion of JPY 574.7 billion Q1 FY2026 revenue. [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202607/20260731_E4.pdf) ## Questions investors ask ### What is aibio.space's Investor Rank for Daiichi Sankyo Company? 8 out of 10, our positive view. The Enhertu-led ADC platform is growing revenue fast with breast cancer approvals, while the I-DXd withdrawal and heavy Enhertu concentration temper the lung cancer case. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### Who is the CEO of Daiichi Sankyo? Hiroyuki Okuzawa is president and CEO of Daiichi Sankyo. He was quoted in that role in the company's August 24, 2026 announcement naming Ken Keller chief commercialization officer. [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202608/20260824_E.pdf) ### Why was the ifinatamab deruxtecan BLA withdrawn? Daiichi Sankyo and MSD withdrew the US application in September 2026 after the FDA said data including the phase 2 IDeate-Lung01 trial did not satisfy requirements for accelerated approval in previously treated ES-SCLC. The phase 3 IDeate-Lung02 trial continues. [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202609/20260925_E.pdf) ### How much did Enhertu sell in the latest quarter? Enhertu revenue, including milestone payments, was JPY 239.8 billion in the April to June 2026 quarter, up 48.9%. Total company revenue was JPY 574.7 billion. [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202607/20260731_E4.pdf) ### What is Daiichi Sankyo's FY2026 guidance? On July 31, 2026 Daiichi Sankyo raised its fiscal 2026 forecast to revenue of JPY 2.34 trillion and operating profit of JPY 320.0 billion, from JPY 2.28 trillion and JPY 315.0 billion. [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202607/20260731_E4.pdf) ### What were the DESTINY-Lung04 results? Enhertu cut the risk of progression or death by 37% versus pembrolizumab plus chemotherapy in first-line HER2-mutant NSCLC, with median PFS of 14.3 versus 8.3 months. Overall survival was 46.9% mature with no observed benefit. [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202609/20260914_E.pdf) ## Legal and investor matters Checked against Daiichi Sankyo Company filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. 1. 2026-09-10 Litigation Tokyo court dismisses NTK's JPY 203 billion damages claim against Daiichi Sankyo Daiichi Sankyo announced that on September 10, 2026 the Tokyo District Court dismissed all claims in a lawsuit by Northern TK Venture (NTK), an indirect subsidiary of IHH Healthcare, against it. NTK filed the suit on October 16, 2023 and later expanded its damages claim to JPY 203,301,807,840. NTK alleged that Daiichi Sankyo interfered with its tender offer for Fortis Healthcare. Daiichi Sankyo says the judgment will have no impact on its financial results and that it will continue to assert its position if NTK appeals. Tokyo District Court · Status: dismissed [Daiichi Sankyo press release, 2026-09-10](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202609/20260910_E2.pdf) 2. 2026-03-10 Litigation Daiichi Sankyo says Seagen patent dispute is concluded after review deadlines pass Daiichi Sankyo announced on March 10, 2026 that its patent dispute with Seagen has concluded. The U.S. Court of Appeals for the Federal Circuit ruled on December 2, 2025 that Seagen's '039 patent was invalid and vacated the Texas infringement judgment and damages award against Daiichi Sankyo. The deadlines for the parties to seek review of the decisions passed on March 2, 2026. U.S. Court of Appeals for the Federal Circuit [Daiichi Sankyo US press release, 2026-03-10](https://daiichisankyo.us/press-releases/-/article/patent-dispute-between-daiichi-sankyo-and-seagen-has-concluded) 3. 2025-12-03 Litigation Federal Circuit vacates Seagen infringement judgment against Daiichi Sankyo On December 2, 2025 the U.S. Court of Appeals for the Federal Circuit reversed an Eastern District of Texas decision that had found Seagen's '039 patent not invalid. It then vacated the related infringement judgment and damages award against Daiichi Sankyo. It also dismissed as moot Seagen's appeal of the January 2024 Patent Office decision that invalidated the challenged claims. Daiichi Sankyo announced the rulings on December 3, 2025. U.S. Court of Appeals for the Federal Circuit · Status: appealed [Daiichi Sankyo press release, 2025-12-03](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202512/20251203_E.pdf) 4. 2025-05-22 Litigation NTK moves to expand damages claim against Daiichi Sankyo to JPY 203 billion Daiichi Sankyo said on May 22, 2025 that Northern TK Venture (NTK), an indirect subsidiary of IHH Healthcare, filed a motion on May 9, 2025 to expand its damages claim in the Tokyo District Court. The suit was filed October 16, 2023 and first sought JPY 20 billion. The expanded claim is JPY 203,301,807,840. Daiichi Sankyo said it believes NTK's claims are without merit and would continue to defend its position. On September 10, 2026 the Tokyo District Court dismissed all of NTK's claims, according to Daiichi Sankyo's later announcement. Tokyo District Court · Status: dismissed [Daiichi Sankyo press release, 2025-05-22](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202505/20250522_E.pdf) ## Pipeline | Program | Indication | Stage | |---|---|---| | Enhertu (trastuzumab deruxtecan) | First-line HER2-mutant non-small cell lung cancer | Phase 3 DESTINY-Lung04 met its primary PFS endpoint; presented at WCLC on September 14, 2026 [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202609/20260914_E.pdf) | | Ifinatamab deruxtecan (I-DXd) | Relapsed extensive-stage small cell lung cancer | US accelerated approval BLA withdrawn Sept 2026; phase 3 IDeate-Lung02 enrolling [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202609/20260925_E.pdf) | | Datroway (datopotamab deruxtecan) | First-line non-squamous NSCLC without actionable alterations (AVANZAR) | Phase 3, readout expected CY2026 H2 [Source](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2026/FY2026Q1_Financial_Results_Presentation_E.pdf) | | Datroway | EGFR-mutated NSCLC after osimertinib (TROPION-Lung15) | Phase 3, readout expected FY2026 H2 [Source](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2026/FY2026Q1_Financial_Results_Presentation_E.pdf) | | Raludotatug deruxtecan (R-DXd) | Platinum-resistant ovarian cancer | Phase 2/3 REJOICE-Ovarian01; update at ESMO 2026 [Source](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202610/20261022_E2.pdf) | ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open TSE:4568 on TradingView](https://www.tradingview.com/symbols/TSE-4568/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/daiichi-sankyo/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Daiichi Sankyo Company (4568): news, pipeline and catalysts", 2026-10-31, https://aibio.space/companies/daiichi-sankyo/